Page last updated: 2024-11-13

sr9243

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR9243: an LXR inverse agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

SR9243 : A sulfonamide resulting from the formal condensation of the sulfonic acid group of mesitylene-2-sulphonic acid with the amino group of 2-(m-bromophenyl)ethylamine in which the nitrogen is substituted by a 4-[m-(methylsulfonyl)phenyl]benzyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	76073169
CHEBI ID	90842
SCHEMBL ID	15773799
MeSH ID	M000610779

Synonyms (35)

Synonym
S7934
CS-4514
CHEBI:90842
n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-n-{[3'-(methylsulfonyl)biphenyl-4-yl]methyl}benzenesulfonamide
sr-9243
sr 9243
SCHEMBL15773799
sr9243
1613028-81-1
AC-29034
HY-16972
5-cyano-2'-{4-[2-(3-methyl-1h-indol-1-yl)ethyl]-1-piperazinyl}-n-[3-(1-pyrrolidinyl)propyl]-3-biphenylcarboximidic acid
J-690219
AKOS026750218
EX-A622
n-(3-bromophenethyl)-2,4,6-trimethyl-n-((3'-(methylsulfonyl)biphenyl-4-yl)methyl)benzenesulfonamide
n-[2-(3-bromophenyl)ethyl]-n-{[4-(3-methanesulfonylphenyl)phenyl]methyl}-2,4,6-trimethylbenzene-1-sulfonamide
sr9243, >=98% (hplc)
n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-n-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]benzenesulfonamide
mfcd29049514
n-(3-bromophenethyl)-2,4,6-trimethyl-n-((3'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide
FT-0700227
BCP15765
n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyln-{[3'-(methylsulfonyl)-4-biphenylyl]methyl} benzenesulfonamide
sr 9243;sr9243
Q27162823
AS-16933
SB19147
NCGC00389085-05
n-[2-(3-bromophenyl)ethyl]-2,4,6-trimethyl-n-[[4-(3-methylsulfonylphenyl)phenyl]methyl]benzenesulfonamide
nsc787081
nsc-787081
nsc810522
nsc-810522
A883123

Research Excerpts

Treatment

Excerpt	Reference	Relevance
"Treatment with SR9243 significantly reduced the severity of hepatic inflammation and ameliorated hepatic fibrosis; simultaneously, body weight, serum glucose, and plasma lipid levels were controlled effectively."	( Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis. Chang, S; Huang, FZ; Huang, P; Jiang, XL; Kaluba, B; Mao, LF; Tang, XF; Zhang, ZP, 2018)	1.1

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
liver X receptor inverse agonist	An inverse agonist that binds to the same receptor as a liver X receptor agonist, but which induces a pharmacological response opposite to that agonist.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
sulfone	An organosulfur compound having the structure RS(=O)2R (R =/= H).
bromobenzenes	A member of the class of benzenes that is benzene substituted by at least one bromo group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (57.14)	24.3611
2020's	3 (42.86)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	20.19 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.64 (4.65)
Search Engine Demand Index	15.26 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (20.19)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.17	1	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2.21	1	indazole
alpha-asarone asarone: structure in Merck Index, 9th ed, #847. asarone : A phenylpropanoid that is benzene substituted by methoxy groups at positions 1, 2 and 4 and a propen-1-yl group at position 5. It has been isolated from Acorus.. alpha-asarone : The trans-isomer of asarone.	2.17	1	asarone	anticonvulsant; GABA modulator
way 252623 2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole: a partial LXR agonist	2.21	1
sr9238 SR9238: liver-selective LXR inverse agonist that suppresses hepatic steatosis; structure in first source	2.41	1

Condition	Relationship Strength	Studies
Colorectal Cancer [description not available]	7.6	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.6	1
Lesion of Sciatic Nerve [description not available]	2.17	1
Nerve Pain [description not available]	2.17	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.17	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.17	1
Fatty Liver, Nonalcoholic [description not available]	2.17	1
Innate Inflammatory Response [description not available]	2.17	1
Cirrhosis, Liver [description not available]	2.17	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.17	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.17	1
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.17	1
Adenocarcinoma Of Kidney [description not available]	2.21	1
Cancer of Kidney [description not available]	2.21	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.21	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.21	1
Benign Neoplasms [description not available]	2.11	1
Weight Reduction [description not available]	2.11	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.11	1
Weight Loss Decrease in existing BODY WEIGHT.	2.11	1

chemdatabank.com